Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Alzheimer’s Association. 2017 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2017, 13, 325–373. [Google Scholar]
- Mizenko, A.J.; Tefft, B.C.; Arnold, L.S.; Grabowski, J. Older American Drivers and Traffic Safety Culture: A Longroad Study; AAA Foundation for Traffic Safety: Washington, DC, USA, 2014. [Google Scholar]
- Cox, D.J.; Quillian, W.C.; Thorndike, F.P.; Kovatchev, B.P.; Hanna, G. Evaluating driving performance of outpatients with Alzheimer disease. J. Am. Board Fam. Pract. 1998, 11, 264–271. [Google Scholar] [CrossRef] [PubMed]
- Duchek, J.M.; Hunt, L.; Ball, K.; Buckles, V.; Morris, J.C. Attention and driving performance in Alzheimer’s disease. J. Gerontol. 1998, 53B, P130–P141. [Google Scholar] [CrossRef]
- Reinach, S.J.; Rizzo, M.; McGehee, D.V. Driving with Alzheimer disease: The anatomy of a crash. Alzheimer Dis. Assoc. Disord. 1997, 11, 21–27. [Google Scholar] [CrossRef] [PubMed]
- Sperling, R.A.; Aisen, P.S.; Beckett, L.A.; Bennett, D.A.; Craft, S.; Fagan, A.M.; Iwatsubo, T.; Jack, C.R., Jr.; Kaye, J.; Montine, T.J.; et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011, 7, 280–292. [Google Scholar] [CrossRef] [PubMed]
- Roe, C.M.; Barco, P.P.; Head, D.M.; Ghoshal, N.; Selsor, N.; Babulal, G.M.; Fierberg, R.; Vernon, E.K.; Shulman, N.; Johnson, A.; et al. Amyloid imaging, cerebrospinal fluid biomarkers predict driving performance among cognitively normal individuals. Alzheimer Dis. Assoc. Disord. 2017, 31, 69–72. [Google Scholar] [CrossRef] [PubMed]
- Roe, C.M.; Babulal, G.M.; Head, D.M.; Stout, S.H.; Vernon, E.K.; Ghoshal, N.; Garland, B.; Barco, P.P.; Williams, M.M.; Johnson, A.; et al. Preclinical Alzheimer’s disease and longitudinal driving decline. Alzheimer’s Dement. 2017, 3, 74–82. [Google Scholar] [CrossRef] [PubMed]
- Jack, C.R.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Feldman, H.H.; Frisoni, G.B.; Hampel, H.; Jagust, W.J.; Johnson, K.A.; Knopman, D.S.; et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016, 87, 539–547. [Google Scholar] [CrossRef] [PubMed]
- Jack, C.R., Jr.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018, 14, 535–562. [Google Scholar] [CrossRef] [PubMed]
- Roe, C.M.; Babulal, G.M.; Mishra, S.; Gordon, B.A.; Stout, S.H.; Ott, B.R.; Carr, D.B.; Ances, B.M.; Morris, J.C.; Benzinger, T.L.S. Tau and amyloid positron emission tomography imaging predict driving performance among older adults with and without preclinical Alzheimer disease. J. Alzheimer’s Dis. 2017, 3, 1–6. [Google Scholar]
- Morris, J.C. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993, 43, 2412–2414. [Google Scholar] [CrossRef] [PubMed]
- Owsley, C.; Stalvey, B.; Wells, J.; Sloane, M.E. Older drivers and cataract: Driving habits and crash risk. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 1999, 54, M203–M211. [Google Scholar] [CrossRef]
- Hunt, L.A.; Carr, D.; Duchek, J.M.; Grant, E.A.; Buckles, V.; Murphy, C.F.; Morris, J.C. Reliability and validity of the washington university road test: A performance-based assessment for drivers with dementia of the Alzheimer type. Arch. Neurol. 1997, 54, 707–712. [Google Scholar] [CrossRef] [PubMed]
- Vos, S.J.B.; Xiong, C.; Visser, P.J.; Jasielec, M.S.; Hassenstab, J.; Grant, E.A.; Cairns, N.J.; Morris, J.C.; Holtzman, D.M.; Fagan, A.M. Preclinical Alzheimer’s disease and its outcome: A longitudinal cohort study. Lancet Neurol. 2013, 12, 957–965. [Google Scholar] [CrossRef]
- Jack, C.R.; Knopman, D.S.; Chételat, G.; Dickson, D.; Fagan, A.M.; Frisoni, G.B.; Jagust, W.; Mormino, E.C.; Petersen, R.C.; Sperling, R.A.; et al. Suspected non-Alzheimer disease pathophysiology-concept and controversy. Nat. Rev. Neurol. 2016, 12, 117–124. [Google Scholar] [CrossRef] [PubMed]
- Dani, M.; Brooks, D.J.; Edison, P. Suspected non Alzheimer’s pathology—Is it non-Alzheimer’s or non-amyloid? Ageing Res. Rev. 2017, 36, 20–31. [Google Scholar] [CrossRef] [PubMed]
- Liddle, J.; Bennett, S.; Allen, S.; Lie, D.C.; Standen, B.; Pachana, N.A. The stages of driving cessation for people with dementia: Needs and challenges. Int. Psychogeriatr. 2013, 25, 2033–2046. [Google Scholar] [CrossRef] [PubMed]
- Eby, D.W.; Silverstein, N.M.; Molnar, L.J.; LeBlanc, D.; Adler, G. Driving behaviors in early stage dementia: A study using in-vehicle technology. Accid. Anal. Prev. 2012, 49, 330–337. [Google Scholar] [CrossRef] [PubMed]
- Hird, M.A.; Egeto, P.; Fischer, C.E.; Naglie, G.; Schweizer, T.A.; Pachana, N. A systematic review and meta-analysis of on-road simulator and cognitive driving assessment in Alzheimer’s disease and mild cognitive impairment. J. Alzheimer’s Dis. 2016, 53, 713–729. [Google Scholar] [CrossRef] [PubMed]
AD (N = 25) | AD Pathology (N = 25) | Normal (N = 73) | SNAP (N = 34) | Total (N = 157) | |||||
---|---|---|---|---|---|---|---|---|---|
Mean/N | SD/% | Mean/N | SD/% | Mean/N | SD/% | Mean/N | SD/% | p-Value | |
Demographics | |||||||||
Age, y | 73.9 | 5.2 | 72.5 | 5.2 | 71.8 | 4.0 | 73.5 | 5.8 | 0.159 |
Education, y | 16.0 | 2.5 | 16.4 | 2.8 | 16.6 | 2.6 | 16.0 | 2.5 | 0.612 |
Women, N | 10 | 40.0% | 14 | 56.0% | 35 | 48.0% | 20 | 58.8% | 0.469 |
Race, N | 0.940 | ||||||||
AA | 2 | 8.0% | 3 | 12.0% | 10 | 13.7% | 4 | 11.8% | |
Caucasian | 23 | 92.0% | 22 | 88.0% | 62 | 84.9% | 30 | 88.2% | |
More than one race | 0 | 0.0% | 0 | 0.0% | 1 | 1.4% | 0 | 0.0% | |
APOE4 | 13 | 52.0% | 12 | 48.0% | 13 | 17.8% | 34 | 17.7% | <0.001 |
Biomarker values | |||||||||
Amyloid positive, N | |||||||||
Adjusted Aβ42 | −1.1 | 0.4 | −1.0 | 0.5 | 0.4 | 0.8 | 0.7 | 0.8 | <0.001 |
tau, pg/mL | 691.2 | 235.5 | 242.1 | 69.4 | 234.5 | 55.1 | 432.3 | 97.4 | <0.001 |
ptau181, pg/mL | 111.2 | 30.7 | 43.7 | 11.1 | 46.3 | 9.8 | 77.5 | 20.2 | <0.001 |
Psychometric performance | |||||||||
SRT Free Recall | 29.7 | 8.2 | 32.3 | 4.8 | 32.4 | 5.6 | 31.9 | 5.5 | 0.249 |
Trailmaking A | 30.9 | 10.7 | 29.2 | 9.5 | 28.9 | 7.9 | 29.8 | 7.8 | 0.776 |
Trailmaking B | 83.0 | 33.3 | 75.7 | 29.3 | 76.1 | 30.5 | 79.5 | 30.8 | 0.805 |
Animal Naming | 20.3 | 6.9 | 20.3 | 4.9 | 22.0 | 6.0 | 21.4 | 5.1 | 0.630 |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Roe, C.M.; Babulal, G.M.; Stout, S.H.; Carr, D.B.; Williams, M.M.; Benzinger, T.L.S.; Fagan, A.M.; Holtzman, D.M.; Ances, B.M.; Morris, J.C. Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease. Geriatrics 2018, 3, 23. https://doi.org/10.3390/geriatrics3020023
Roe CM, Babulal GM, Stout SH, Carr DB, Williams MM, Benzinger TLS, Fagan AM, Holtzman DM, Ances BM, Morris JC. Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease. Geriatrics. 2018; 3(2):23. https://doi.org/10.3390/geriatrics3020023
Chicago/Turabian StyleRoe, Catherine M., Ganesh M. Babulal, Sarah H. Stout, David B. Carr, Monique M. Williams, Tammie L. S. Benzinger, Anne M. Fagan, David M. Holtzman, Beau M. Ances, and John C. Morris. 2018. "Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease" Geriatrics 3, no. 2: 23. https://doi.org/10.3390/geriatrics3020023